Holen Sie sich die Stockscreener-App
1.57
3.29%
0.05
Handel nachbörslich:
1.56
-0.01
-0.64%
Schlusskurs vom Vortag:
$1.52
Offen:
$1.53
24-Stunden-Volumen:
873.13K
Relative Volume:
0.54
Marktkapitalisierung:
$60.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-77.91M
KGV:
-0.7759
EPS:
-2.0234
Netto-Cashflow:
$-65.33M
1W Leistung:
+21.71%
1M Leistung:
+1.29%
6M Leistung:
-17.80%
1J Leistung:
+3.97%
1-Tages-Spanne:
$1.52
$1.62
1-Wochen-Bereich:
$1.315
$1.62
52-Wochen-Spanne:
$1.05
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.57 | 58.89M | 0 | -77.91M | -65.33M | -2.0234 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Aug Intraday: Is Acrivon Therapeutics Inc a good ESG investmentQuarterly Profit Review & Low Risk High Win Rate Picks - baoquankhu1.vn
ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
AI Stocks: Can Acrivon Therapeutics Inc ride the EV wave2026 Earnings Impact & Community Trade Idea Sharing Platform - baoquankhu1.vn
We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Sahm
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress - Investing.com Australia
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress By Investing.com - Investing.com South Africa
[SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Research Analysts Set Expectations for ACRV Q1 Earnings - MarketBeat
If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV) - Stock Titan
ACRV Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: What is Acrivon Therapeutics Incs 5 year growth outlook2026 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Form 4 Acrivon Therapeutics Inc For: 4 March By Investing.com - Investing.com Australia
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates - MarketBeat
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus - Investing.com UK
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus By Investing.com - Investing.com Canada
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Acrivon Highlights Positive ACR-368 Data and 2025 Results - TipRanks
ACRV: 52% response rate in serous endometrial cancer and robust cash reserves support ongoing growth - TradingView
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million - tradingview.com
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Acrivon Therapeutics (ACRV) posts 2025 results, 52% ACR-368 response and $118.6M cash - Stock Titan
Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan
Acrivon Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $77.9M Net Loss - TradingView
ACRV: Net loss narrowed to $77.9M in 2025; cash runway extends into Q2 2027 - TradingView
Oncology pipeline and AP3 proteomics strategy at Acrivon (NASDAQ: ACRV) - Stock Titan
ACRV Q4'25 Earnings: revenue estimate is 166.29K USD - tradingview.com
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday - MarketBeat
Acrivon Therapeutics, Inc. (ACRV) upgraded to buy: Here's why - MSN
Acrivon Therapeutics to Present Pre-Clinical Data on ACR-368 and ACR-2316 Synergy with ADCs and Immune Checkpoint Inhibitors at 2026 AACR Annual Meeting - geneonline.com
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at - GlobeNewswire
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - chartmill.com
Dow Update: Will Acrivon Therapeutics Inc benefit from green energy policiesTrade Entry Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Cancer drug combo clears tumors in mice in Acrivon study - Stock Titan
EPS Watch: Is Acrivon Therapeutics Inc gaining market shareWatch List & Consistent Return Investment Signals - baoquankhu1.vn
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Acrivon Therapeutics (ACRV) Stock Analysis Report | Financials & Insights - Benzinga Japan
Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN
Gains Report: What is Acrivon Therapeutics Incs 5 year growth outlookWeekly Risk Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026Slideshow - Seeking Alpha
Acrivon Therapeutics Highlights ACR-368’s ~50% Response in Serous Endometrial Cancer at TD Cowen Conf. - Defense World
Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan
Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares - Stock Titan
Executive Mary Miller at Acrivon Therapeutics (ACRV) granted 129,760 options - Stock Titan
Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares - Stock Titan
Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan
Acrivon Therapeutics (ACRV) grants stock options to CEO and EVP - Stock Titan
ACRV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acrivon Therapeutics, Inc. (ACRV) Raised to Buy: Discover the Reasons - Bitget
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acrivon Therapeutics Inc-Aktie (ACRV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levy Adam D. | Chief Financial Officer |
Jan 14 '26 |
Buy |
1.70 |
8,832 |
14,999 |
20,983 |
| Devroe Eric | Chief Operating Officer |
Jan 13 '26 |
Buy |
1.72 |
10,000 |
17,218 |
75,308 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 30 '25 |
Sale |
1.41 |
437,881 |
617,412 |
3,403,025 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):